News | September 27, 2024
Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress
The company will also share results in two additional posters for deuruxolitinib
The company will also share results in two additional posters for deuruxolitinib
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Launch of 20 new medicines expected by 2030
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Subscribe To Our Newsletter & Stay Updated
